Skip to main content
Pharmicell Co.,Ltd. logo

Pharmicell Co.,Ltd. — Investor Relations & Filings

Ticker · 005690 ISIN · KR7005690003 KO Manufacturing
Open in API
Filings indexed 275 across all filing types
Latest filing 2022-09-19 Report Publication Anno…
Country KR South Korea
Listing KO 005690

About Pharmicell Co.,Ltd.

https://www.pharmicell.com/eng/

Pharmicell Co., Ltd. is a biopharmaceutical company specializing in stem cell technology and advanced bio-based materials. The company is a pioneer in regenerative medicine, having developed Hearticellgram-AMI, the world's first approved stem cell therapy for acute myocardial infarction. Its core business includes the development of stem cell therapeutics, a stem cell banking service for adult and cord blood cells, and a line of cosmetics based on stem cell culture media. A significant division focuses on fine chemicals, manufacturing and supplying critical raw materials for the pharmaceutical industry, such as nucleosides, mPEGs, and oligonucleotides for gene therapies. The company also produces eco-friendly flame retardants for industrial use.

Recent filings

Filing Released Lang Actions
기업설명회(IR)개최(안내공시)
Report Publication Announcement Classification · 100% confidence The document is a short announcement (755 characters) regarding the scheduling and logistics of an upcoming Investor Relations (IR) event (Corporate Day). It provides the date, location, and purpose of the meeting, and explicitly states that the actual presentation materials will be posted on the company website at a later time. According to the 'Menu vs Meal' rule, this is an announcement of an event/report rather than the presentation itself, fitting the criteria for a Report Publication Announcement (RPA) or general regulatory filing. Given the specific nature of announcing an IR event, RPA is the most accurate classification.
2022-09-19 Korean
반기보고서 (2022.06)
Interim / Quarterly Report Classification · 100% confidence The document is a '반기보고서' (Semi-annual Report) for Pharmicell Co., Ltd., covering the period from January 1, 2022, to June 30, 2022. It contains detailed financial information, business operations, management discussions, and governance details, which aligns with the definition of an Interim/Quarterly Report (IR). H1 2022
2022-08-16 Korean
[기재정정]주요사항보고서(유형자산양수결정)
M&A Activity Classification · 100% confidence The document is a regulatory filing from Pharmicell Co., Ltd. regarding an amendment to a previous disclosure about the acquisition of tangible assets (land and buildings). It details specific changes to the acquisition date and payment schedule. Since this is a formal regulatory disclosure regarding a corporate transaction (asset acquisition) filed with the Korea Exchange, and it does not fit into specific categories like M&A (which usually refers to company mergers/takeovers) or other specialized categories, it falls under the general regulatory filing category.
2022-07-04 Korean
주식등의대량보유상황보고서(일반)
Major Shareholding Notification Classification · 100% confidence The document is a '주식등의 대량보유상황보고서' (Report on Large Shareholding of Stocks, etc.), which is a standard regulatory filing in South Korea under the Capital Markets Act. It details the change in shareholding percentage by a major shareholder (Kim Hyun Soo) and his special related parties in Pharmicell Co., Ltd. This type of filing is specifically categorized as a 'Major Shareholding Notification' (MRQ) in the provided schema.
2022-06-28 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 100% confidence The document is a Korean regulatory filing titled '임원ㆍ주요주주 특정증권등 소유상황보고서' (Report on Ownership of Specific Securities by Executives and Major Shareholders). This is a standard disclosure form required by the Financial Supervisory Service (FSS) in South Korea when a company insider (director or major shareholder) trades company shares. This corresponds to the 'Director's Dealing' category.
2022-06-28 Korean
최대주주등소유주식변동신고서
Major Shareholding Notification Classification · 100% confidence The document is a 'Report of Change in Shareholding by Major Shareholders' (최대주주등소유주식변동신고서) filed with the Korean regulatory authority (DART). It details specific share transactions (purchases) by major shareholders and directors. This falls under the category of 'Major Shareholding Notification' (MRQ) as it reports changes in significant share ownership levels and insider holdings.
2022-06-28 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.